These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 10873086)
1. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Cox G; Jones JL; O'Byrne KJ Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086 [TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714 [TBL] [Abstract][Full Text] [Related]
4. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492 [TBL] [Abstract][Full Text] [Related]
5. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Cortas T; Eisenberg R; Fu P; Kern J; Patrick L; Dowlati A Lung Cancer; 2007 Mar; 55(3):349-55. PubMed ID: 17161498 [TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426 [TBL] [Abstract][Full Text] [Related]
8. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573 [TBL] [Abstract][Full Text] [Related]
9. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099 [TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134 [TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Hsu CP; Shen GH; Ko JL Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461 [TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994 [TBL] [Abstract][Full Text] [Related]
15. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Koukourakis MI; Giatromanolaki A; Thorpe PE; Brekken RA; Sivridis E; Kakolyris S; Georgoulias V; Gatter KC; Harris AL Cancer Res; 2000 Jun; 60(11):3088-95. PubMed ID: 10850461 [TBL] [Abstract][Full Text] [Related]
17. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA Am J Clin Pathol; 2006 Jun; 125(6):860-5. PubMed ID: 16690485 [TBL] [Abstract][Full Text] [Related]
18. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions]. Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813 [TBL] [Abstract][Full Text] [Related]
19. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]